Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCORI Following Intent Of Legislators, But Needs To Be Careful In Defining “Patient-Centered Outcomes Research” – Former Senate Staffer

Executive Summary

A former member of the Senate Finance Committee staff that contributed to the writing of the health care reform law that formed the Patient-Centered Outcomes Research Institute believes the institute is following the intent laid out by the committee, but has concerns on the current draft definition.

You may also be interested in...



PCORI-Identified Themes From Early Comment Analysis Avoid Pharma Industry Concerns

The Patient-Centered Outcomes Research Institute identifies themes from early analysis of comments received on its Methodology Committee report, but it is not clear whether these themes address concerns raised by the pharmaceutical industry.

PCORI In 2012: The Year Of Stakeholder Engagement

With a draft document containing the national priorities and research agenda now available for comment, PCORI will focus in 2012 on discussing with stakeholders what specific research should be funded. By the end of 2012 PCORI expects to have a portfolio of research activities under way.

PCORI’s Slow Start On Comparative Research May Protect It From Political Heat

The Patient-Centered Outcomes Research Institute’s slow ramp-up to being in a position to fund comparative research projects may actually help it survive a heated political environment in an election year.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel